Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

NCT03480932 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Sofosbuvir
DRUG: Daclatasvir
DRUG: Pegylated Interferon alfa-2a

Sponsor

Johns Hopkins Bloomberg School of Public Health

Collaborators

[object Object]
[object Object]